-
Part 2 | Session 3 API-CAT: Reduced Vs Full Dose Apixaban for Cancer-Associated Thrombosis
-
Part 2 | Session 4 FRESH-UP: Liberal Intake Vs Fluid Restriction in Chronic Heart Failure
-
Part 2 | Session 5 SOUL: Semaglutide in Patients with T2D
-
Part 2 | Session 6 BHF PROTECT-TAVI: Cerebral Embolic Protection in TAVI
-
Part 3 | Session 1 The Phase 3 REVERSE-IT Trial
-
Part 3 | Session 2 EVOLUT Low Risk: 5Y Outcomes After TAVR or SAVR in Low-Risk Patients with AS
-
Part 3 | Session 3 SMART-CHOICE 3: Clopidogrel vs Aspirin Monotherapy in High-Risk PCI Patients
-
Part 3 | Session 6 MIGHTy-Heart: Mobile Integrated Health in Heart Failure
-
Part 3 | Session 10 Lifetime Benefit by Control of Modifiable Risk Factors
-
Part 3 | Session 11 CardiAMP-HF: Autologous Cell Therapy in Patients With HFrEF
-
Part 4 | Session 1 4 Trials That Will Change My Practice with Dr Ambarish Pandey
-
Part 4 | Session 2 4 Trials That Will Change My Practice with Dr Dipti Itchhaporia
-
Part 1 | Session 1 View from the Thoraxcenter: What's Hot at ACC.25?
-
Part 1 | Session 2 View from the Thoraxcenter: ACC 25 Wrap-Up
-
Part 2 | Session 1 ADVANCE-HTN: Lorundrostat in Patients with Uncontrolled Hypertension
ACC 25 - STRIDE shows subcutaneous semaglutide improved walking ability and related quality of life in patients with both type 2 diabetes and peripheral arterial disease (PAD) with intermittent claudication symptoms.
Late-Breaker host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Dr Marc Bonaca (University of Colorado School of Medicine, Aurora, CO, US) to discuss the findings from STRIDE, a randomized-double blind placebo-controlled trial investigating the effect of semaglutide on walking ability in people with PAD and type 2 diabetes. The primary outcome was the change in maximum walking distance on constant load treadmill test from baseline to 52 weeks. Secondary outcomes included pain-free walking distance changes, quality of life measures, metabolic parameters, vascular measurements and follow-up measures at week 57.
Findings showed significantly improved maximum walking distance and pain-free walking distance, meeting prespecified criteria for a clinically meaningful change. The study also showed significant improvement in all supportive secondary outcomes, including qualify of life measures.
Recorded Onsite at ACC 25, Chicago.
Editors: Yazmin Sadik, Jordan Rance
Videographers: Dan Brent, David Ben-Harosh
Support: This is an independent interview produced by Radcliffe Cardiology.
Keep up-to-date with our video collection on the American College of Cardiology's 74th annual congress, covering late-breaking science, featured science and clinical horizon sessions. Don't miss the preview and wrap-up of the congress in our View From the Thoraxcenter series, concise Expert Interviews with select faculty offering take-home messages for practice, and our Highlights summarising the most influential trials.
More from this programme
Faculty Biographies

Marc P Bonaca
Director of Vascular Research and an Associate Professor of Medicine
Dr Marc Bonaca is a Cardiologist and Vascular Medicine Specialist who serves as the Executive Director of CPC Clinical Research and CPC Community Health which is an Academic Research Organization created by and affiliated with the University of Colorado Anschutz Medical Campus. He is the Director of Vascular Research and an Associate Professor of Medicine at the University of Colorado School of Medicine and the inaugural holder of the William R. Hiatt Endowed Chair in Cardiovascular Research. CPC is a core resource of the University of Colorado research and community outreach infrastructure.
Dr Bonaca earned his medical degree from the University of Connecticut School of Medicine and his Masters in Public Health at Harvard University. He served as a Medical House Officer at Brigham and Women’s Hospital and Harvard Medical School. Following his medical residency training, he completed a fellowship in cardiology and a fellowship in vascular medicine at Brigham and Women’s…

Harriette Van Spall
Associate Professor of Medicine, Director of E-Health and Virtual Care
Dr Harriette Van Spall is an Associate Professor of Medicine and cardiologist and serves as Director of E-Health at McMaster University, Canada. She completed her medical and postgraduate clinical training at the University of Toronto and earned a Master of Public Health degree at Harvard University, US. Dr Van Spall is a Canadian Institutes of Health Research-funded clinical trialist and researcher with a focus on heart failure, health services, and health disparities.
She has garnered more than $4 million in research funding, has won several research awards, and has published her work in high-impact medical journals. She is an invited speaker, media correspondent, and editorial board member active in peer review at several high-impact medications journals and grant funding agencies, including Canadian Institutes of Health Research and Heart and Stroke Foundation of Canada.
Dr Van Spall is an Editorial Board…
Comments